美国与加拿大Treat-All时代HIV男性卡波西肉瘤的临床预测因素与发病率
在北美AIDS队列协作研究中,2009-2019年61 155名HIV男性贡献370 624人年,共262例卡波西肉瘤诊断。KS发病率从132降至43例/10万人年,病毒抑制、近期/未启动ART和CD4≥500与KS率降低相关但关联随时间减弱。结论强调早期HIV诊断与治疗对降低KS负担的重要性,KS驱动因素正在演变。
要点
- 2009-2019年HIV男性KS发病率从132降至43例/10万人年。
- 病毒抑制、CD4≥500和近期/未启动ART与KS率降低相关,但关联随时间减弱。
- KS诊断时病毒未抑制比例和ART≤1年/未治疗比例均下降。
核心结论
- 早期HIV诊断与治疗对降低卡波西肉瘤负担至关重要。
- 与HIV相关因素的关联减弱提示成功管理HIV者日益成为KS患者群体。
- KS驱动因素正在演变,需要患者和人群层面的监测。
研究设计与样本
- 北美AIDS队列协作研究(NA-ACCORD)中HIV男性队列分析。
- 纳入61 155名HIV男性,贡献370 624人年,共262例KS诊断。
- 按病毒抑制(<200 copies/mL)、CD4计数(<500 vs ≥500 cells/mm3)和ART启动时间(<1年/未治疗 vs ≥1年)估计2009-2019年年KS率。
- 使用负二项回归估计发病率比(IRR)及95%CI,用joinpoint回归估计临床因素分布的年平均百分比变化(AAPC)。
主要发现
- KS发病率从2009年132例/10万人年降至2019年43例/10万人年。
- KS诊断时病毒未抑制比例下降10.6%(-15.8%至-4.8%),ART≤1年/未治疗比例从70%降至40%(AAPC -6.3% [-13.8%, 2.1%])。
临床怎么用
- 应重视HIV早期诊断和及时启动ART以降低卡波西肉瘤负担。
- 对已成功管理HIV者仍需监测KS风险,因该群体在KS患者中占比增加。
- 需在患者和人群层面持续监测KS驱动因素的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stagnating decreases in Kaposi sarcoma (KS) among men with HIV (MWH) following Treat-All policies necessitate evaluating changes in clinical drivers of KS. We examined clinical factors and their associations with KS rates among MWH in North America. METHODS: Among MWH in the North American AIDS Cohort Collaboration on Research and Design, we estimated annual KS rates (per 100 000 person-years [PY]) by viral suppression (<200 copies/mL), CD4 count (<500 vs ≥500 cells/mm3), and time since ART initiation (<1 year/naive vs ≥1 year) from 2009-2019. We quantified associations between clinical factors and KS rates using negative binomial regression, estimating incidence rate ratios (IRRs) with 95% CIs. Among MWH with KS, we estimated average annual percentage changes (AAPCs) in clinical factor distribution using joinpoint regression. RESULTS: There were 61 155 MWH (370 624 PY) contributing 262 KS diagnoses. KS decreased from 132 to 43 cases per 100 000 PY between 2009 and 2019. Viral suppression (IRR2009: .09 [95% CI: .04-.20]; IRR2019: .69 [.31-1.54]), recent/no ART initiation (IRR2009: .14 [.07-.30]; IRR2019: 1.16 [.53, 2.56]), and CD4 count ≥500 cells/mm3 (IRR2009: .13 [.05-.31]; IRR2019: .44 [.18-1.10]) were associated with reduced KS rates, attenuating over time. Unsuppressed viral load at KS diagnosis decreased by 10.6% (-15.8%, -4.8%) as did those on ART ≤1 year/naive (70%-40%; AAPC: -6.3% [-13.8%, 2.1%]). CONCLUSIONS: Our findings underscore the importance of early HIV diagnosis/treatment in reducing KS burden. Attenuating associations with HIV factors indicate that those successfully managing HIV increasingly represent KS patients. KS drivers are evolving, requiring patient/population-level monitoring.
引用
- Coburn SB, Silverberg MJ, Lang R, et al. Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada. Clin Infect Dis. 2026. PMID: 40824135. doi:10.1093/cid/ciaf446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。